These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 12916502)
1. Blocking lymphocyte adhesion: new treatment for sticky cases of Crohn disease? Rhee SJ; Bousvaros A J Pediatr Gastroenterol Nutr; 2003 Aug; 37(2):211-3. PubMed ID: 12916502 [No Abstract] [Full Text] [Related]
2. Natalizumab for induction of remission in Crohn's disease. MacDonald JK; McDonald JW Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580 [TBL] [Abstract][Full Text] [Related]
3. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gordon FH; Lai CW; Hamilton MI; Allison MC; Srivastava ED; Fouweather MG; Donoghue S; Greenlees C; Subhani J; Amlot PL; Pounder RE Gastroenterology; 2001 Aug; 121(2):268-74. PubMed ID: 11487536 [TBL] [Abstract][Full Text] [Related]
4. FDA advisers endorse natalizumab for Crohn's disease. Traynor K Am J Health Syst Pharm; 2007 Sep; 64(18):1886, 1888, 1890. PubMed ID: 17823090 [No Abstract] [Full Text] [Related]
5. Natalizumab (Tysabri) for Crohn's disease. Med Lett Drugs Ther; 2008 May; 50(1285):34-6. PubMed ID: 18458669 [No Abstract] [Full Text] [Related]
12. The role of integrin antagonists in the treatment of inflammatory bowel disease. Beniwal-Patel P; Saha S Expert Opin Biol Ther; 2014 Dec; 14(12):1815-23. PubMed ID: 25288228 [TBL] [Abstract][Full Text] [Related]
13. Adalimumab induces and maintains remission in severe, resistant paediatric Crohn disease. Hadziselimovic F J Pediatr Gastroenterol Nutr; 2008 Feb; 46(2):208-11. PubMed ID: 18223382 [No Abstract] [Full Text] [Related]
14. Natalizumab therapy for moderate to severe Crohn disease in adolescents. Hyams JS; Wilson DC; Thomas A; Heuschkel R; Mitton S; Mitchell B; Daniels R; Libonati MA; Zanker S; Kugathasan S; J Pediatr Gastroenterol Nutr; 2007 Feb; 44(2):185-91. PubMed ID: 17255829 [TBL] [Abstract][Full Text] [Related]